ScinoPharm, Sundia MediTech Partner for Pharma Outsourcing in China
ScinoPharm Changshu Pharmaceuticals and Sundia MediTech form an alliance for contract research and manufacturing services in mainland China.
ScinoPharm Changshu Pharmaceuticals and Sundia MediTech have formed a strategic alliance to for contract research and manufacturing Services (CRAMS) in mainland China.
This cooperation combines Sundia’s capabilities in new drug R&D with ScinoPharm’s process R&D and commercial production expertise, especially in the field of highly potent oncological APIs. Under the alliance, both parties will be able to further support customer needs with one-stop solutions for integrated services such as drug development, research, clinical trials, and commercial manufacturing.
Sondia MediTech is a Shanhai-based CRO with a research team of 600 employees. ScinoPharm Changsho, located in the Jiangsu Province in China is a subsidiary of ScinoPharm Taiwan.
Source: ScinoPharm
FDA Reopens Comment Period on HCP Immunogenicity Risk of Follow-on Recombinant Peptides
January 2nd 2025FDA is reopening the comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, until March 3, 2025.
